Stock Region Penny Picks
Stock Region Penny Picks Watchlist: Tuesday, November 4, 2025
Stock Region Penny Picks Watchlist: Tuesday, November 4, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The following content is for informational and entertainment purposes only. It is not financial advice. All opinions expressed are my own and should not be taken as a recommendation to buy or sell any security. Please do your own research before making any investment decisions. Trading stocks involves risk, and you could lose some or all of your investment.
What a day in the markets yesterday. We saw some wild moves, some impressive earnings beats, and some strategic partnerships that could shake things up. Let’s break down the news and see what’s on my radar for today.
The Movers and Shakers
$HTZ (Hertz Global Holdings)
Wow. Just wow. Hertz didn’t just beat earnings; they obliterated them. They reported $0.12 per share when analysts were expecting a measly $0.02. That’s a 471% beat! Even better, it’s a massive turnaround from the loss they posted this time last year. While sales were down slightly, beating revenue estimates is still a win. This is a classic example of a company tightening its belt and executing flawlessly. I’m definitely watching for follow-through momentum here. This kind of earnings surprise can often lead to a multi-day run.
$PTLE (Pioneer Power Solutions)
Another earnings surprise! $PTLE popped over 79% after reporting earnings of $0.05 per share, a big jump from last year. The interesting part here is that sales were actually down 13%. This tells me they’ve become much more efficient and profitable, even with less revenue. It’s a lean, mean, money-making machine. A stock moving this hard on earnings is one to keep a close eye on.
Mergers, Acquisitions, and Partnerships
$EVOK (Evoke Pharma)
Buyout alert! Evoke is being acquired by QOL Medical. This is often good news for shareholders, as acquisitions usually happen at a premium. If you’re holding $EVOK, you’re likely seeing a nice green day. For the rest of us, it’s a reminder that good things can happen to undervalued biotech companies.
$PRLD (Prelude Therapeutics)
This is a big deal. Prelude announced an exclusive option agreement with Incyte, a major player in the biotech space. Incyte is getting the option to license Prelude’s JAK2 inhibitors. When a small company gets a vote of confidence (and potential cash) from a giant like Incyte, the market pays attention. This could be a major catalyst for $PRLD moving forward.
$SAGT (Sagtec Global Limited)
Sagtec is partnering with Kinetic Seas to push the Skilliks AI platform into Southeast Asia. Global expansion is a powerful growth narrative. Tapping into a massive market like Southeast Asia could be a game-changer for Sagtec. I’m adding this one to the watchlist to see how the market digests this partnership news.
$STKH (Steakholder Foods)
Steakholder Foods is acquiring Twine Solutions. This looks like a strategic move to vertically integrate or expand their tech capabilities in the cultured meat space. Acquisitions can be complex, but if the synergy is there, it can create significant long-term value. One to watch.
Biotech & Pharma News
$RLMD (Relmada Therapeutics)
Positive FDA feedback is like gold in the biotech world. Relmada announced the FDA is on board with two potential study paths for its bladder cancer treatment. This de-risks their clinical trial process significantly and provides a clearer path to potential approval. Any time the FDA gives a green light like this, it’s a major bullish signal.
$SCNX (Scilex Holding)
More access means more sales. Scilex got its oral suspension, Arbli, added to key national payor formularies. This is huge for commercial rollout. Getting insurance to cover your drug is one of the biggest hurdles for a pharma company. With expanded Medicare and commercial coverage, $SCNX could see a significant revenue boost.
$KTTA (Pasithea Therapeutics)
$KTTA announced the activation of a clinical trial site at the University of Alabama for its Phase 1/1b trial. Progress in clinical trials is the lifeblood of developmental-stage biotechs. While it’s still early days, consistent progress is exactly what you want to see.
$ABP (Abpro)
Get ready for data. Abpro will be presenting preclinical data for its next-gen cancer treatment at the SITC conference this week (Nov 6-10). Conference presentations are often major catalysts. Positive data could send this stock flying. Keep a very close eye on $ABP.
Other Notable Mentions
$LGCL (Lucas GC Ltd): This Hong Kong-based company was granted a U.S. patent for its AI-based testing platform. Patents create a protective moat around a company’s technology and add significant intellectual property value.
$LSTA (Lisata Therapeutics): Lisata is getting some shine from its partner, Catalent, which reported positive preclinical data for combinations involving Lisata’s Certepetide. It’s always a good sign when your partners are highlighting the value of your assets.
$CAPT (Captivision, Inc.): Nasdaq has given Captivision another extension to get its filings in order. This isn’t great news, as it signals some internal issues, but it’s better than being delisted. It’s a lifeline, but the company still needs to get its act together. High risk here.
That’s a wrap for this morning’s watchlist! It’s a busy market with plenty of opportunities. Stay sharp, manage your risk, and let’s go make some money.
Final Disclaimer: Remember, investing in the stock market carries inherent risks. The stocks mentioned above are part of a watchlist and are not direct recommendations. Past performance is not indicative of future results. Always conduct your own thorough due diligence before making any investment decisions.